human allogeneic myeloid progenitor cells (CLT-008) / Cellerant Therap - LARVOL DELTA

DECREASED INCIDENCE OF INFECTION, USE OF ANTIBACTERIALS AND DAYS IN HOSPITAL AFTER ADMINISTRATION OF CLT-008 MYELOID PROGENITOR CELLS TO SUBJECTS RECEIVING AML INDUCTION THERAPY: PHASE 2 STUDY RESULTS (EHA 2018) - "The incidence of infections, use of antibacterial agents and days in hospital were decreased in subjects receiving CLT-008. Myeloid progenitors may provide a new option to reduce infections in AML patients undergoing induction therapy."

Clinical • P2 data • Acute Myelogenous Leukemia

A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML. (ASCO 2018) - P2; "Subjects receiving CLT-008 showed a decreased incidence of infections and days in hospital suggesting that myeloid progenitors may provide a new option to reduce infections in AML patients undergoing induction therapy."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Phase 2 Trial Shows Cell Therapy May Prevent Infections in Leukemia Patients (Weill Cornell Medicine) - "'This cell therapy has great potential to help AML patients by reducing their infections, lengthof hospital stays, use of antibiotics, and development of antibiotic resistance-leading to improved outcomes for them overall,' said lead author Dr. Pinkal Desai...."

P2 data

Effect of Myeloid Progenitor Cell Product on the Risk of Infection During Induction Chemotherapy for AML (THE ASCO POST) - P2, N=120; "In a phase II trial reported in the Journal of Clinical Oncology, Desai et al found that the addition of the myeloid progenitor cell product romyelocel-L to granulocyte colony-stimulating factor (G-CSF) reduced the incidence of infection and antimicrobial use vs G-CSF alone during induction chemotherapy in acute myeloid leukemia (AML)....The investigators concluded: 'Subjects receiving romyelocel-L showed a decreased incidence of infections, antimicrobial use, and hospitalization, suggesting that romyelocel-L may provide a new option to reduce infections in patients with AML undergoing induction therapy.'"

P2 data

Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. (PubMed, J Clin Oncol) - "Subjects receiving romyelocel-L showed a decreased incidence of infections, antimicrobial use, and hospitalization, suggesting that romyelocel-L may provide a new option to reduce infections in patients with AML undergoing induction therapy."

Clinical • Journal • P2 data • Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Neutropenia • Oncology

Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia (clinicaltrials.gov) - P2; N=160; Recruiting; Sponsor: Cellerant Therapeutics; Trial primary completion date: Dec 2016 ➔ Dec 2017

Trial primary completion date • Acute Myelogenous Leukemia • Biosimilar • Hematological Malignancies • Leukemia • Oncology

Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia (clinicaltrials.gov) - P2; N=146; Not yet recruiting; Sponsor: Cellerant Therapeutics

New P2 trial • Acute Myelogenous Leukemia • Biosimilar • Hematological Malignancies • Leukemia • Oncology

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy (clinicaltrials.gov) - P1; N=30; Completed; Sponsor: Cellerant Therapeutics; Active, not recruiting -> Completed

Trial completion • Biosimilar • Graft versus Host Disease • Hematological Malignancies • Leukemia • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology